{
  "meta": {
    "title": "90_Myeloproliferative_Disorders_And_Aplastic_Anemia",
    "url": "https://brainandscalpel.vercel.app/90-myeloproliferative-disorders-and-aplastic-anemia-238b86df.html",
    "scrapedAt": "2025-11-30T12:29:17.631Z"
  },
  "questions": [
    {
      "text": "According to WHO 2022 classification, which of the following is not a chronic myeloproliferative neoplasm?",
      "choices": [
        {
          "id": 1,
          "text": "Chronic myeloid leukemia"
        },
        {
          "id": 2,
          "text": "Chronic eosinophilic leukemia"
        },
        {
          "id": 3,
          "text": "Essential thrombocythemia"
        },
        {
          "id": 4,
          "text": "Chronic lymphocytic leukemia"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>Chronic lymphocytic leukemia (<strong>CLL</strong>) is a <strong>lymphoid</strong> neoplasm. It is not a myeloproliferative neoplasm.</p>\n<p><strong>Myeloproliferative</strong> neoplasms (MPN) are a group of disorders that cause an <strong>increased</strong> number of <strong>red blood cells</strong>, <strong>white blood cells</strong>, or <strong>platelets</strong>.&nbsp;According to 5th edition WHO classification (2022), myeloproliferative neoplasms consist of the following:</p>\n<ul>\n<li>Chronic myeloid leukemia (CML)</li>\n<li>Polycythemia vera (PV)</li>\n<li>Primary myelofibrosis (PMF)</li>\n<li>Essential thrombocythemia</li>\n<li>Juvenile myelomonocytic leukemia (JMML)</li>\n<li>Chronic neutrophilic leukemia (CNL)</li>\n<li>Chronic eosinophilic leukemia</li>\n<li>Myeloproliferative neoplasm, not otherwise specified</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4286",
      "difficulty": "medium"
    },
    {
      "text": "What is the most common myeloproliferative neoplasm?",
      "choices": [
        {
          "id": 1,
          "text": "Chronic myeloid leukemia"
        },
        {
          "id": 2,
          "text": "Primary myelofibrosis"
        },
        {
          "id": 3,
          "text": "Essential thrombocytosis"
        },
        {
          "id": 4,
          "text": "Polycythemia vera"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The <strong>most common</strong> myeloproliferative neoplasm is&nbsp;<strong>polycythemia vera.&nbsp;</strong></p>\n<p>It is a hematopoietic stem cell disorder that is characterized by uncontrolled proliferation of the red blood cells in the body. It is also frequently associated with an increase in white blood cells and platelets.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4308",
      "difficulty": "medium"
    },
    {
      "text": "During a routine health checkup, the following lab reports were obtained for a young male patient. What will be your next step in the evaluation?<div class='question-desc-html'><p>Hb: 17 g/dl</p>\n<p>TLC: 5500 /&mu;L</p>\n<p>Platelets: 1,69,000 /&mu;L</p></div>",
      "choices": [
        {
          "id": 1,
          "text": "Perform bone marrow aspiration"
        },
        {
          "id": 2,
          "text": "Measure RBC mass"
        },
        {
          "id": 3,
          "text": "Measure arterial oxygen saturation"
        },
        {
          "id": 4,
          "text": "Look for JAK2 mutation"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>This patient has increased Hb and normal WBCs and platelets. The next step is to<strong> measure&nbsp;RBC mass</strong>&nbsp;to evaluate for&nbsp;polycythemia.</p>\n<p>A person has to be evaluated for <strong>polycythemia</strong> if there is:</p>\n<ul>\n<li><strong>Increased hemoglobin:</strong>&nbsp;&gt;16.5 g/dL in men or &gt;16.0 g/dL in women, (or)</li>\n<li><strong>Increased hematocrit:</strong>&nbsp;&gt;49 percent in men or &gt;48 percent in women</li>\n</ul>\n<p>This condition is due to either a true increase in the number of RBCs (<strong>absolute polycythemia)</strong> or an apparent increase due to a decrease in the plasma volume (<strong>relative polycythemia</strong>). Both of these conditions can be differentiated by measuring RBC mass (amount of total blood volume that is occupied by RBCs).</p>\n<p>In patients with absolute polycythemia, <strong>erythropoietin </strong>(EPO)&nbsp;levels must be measured.</p>\n<ul>\n<li><strong>Primary</strong> polycythemia - <strong>low or normal</strong> EPO levels</li>\n<li><strong>Secondary</strong> polycythemia - <strong>elevated</strong> EPO levels</li>\n</ul><hr><h3>Related Pearl: WHO Polycythemia Vera Criteria</h3><p><span><strong>Major criteria:</strong></span></p>\n<p>1. Hemoglobin <strong>&gt;16.5 g/dL</strong> in men</p>\n<p>&nbsp; &nbsp; &nbsp;Hemoglobin <strong>&gt;16.0 g/dL</strong> in women&nbsp;</p>\n<p>Or</p>\n<p>&nbsp; &nbsp; &nbsp;Hematocrit <strong>&gt;49%</strong> in men</p>\n<p>&nbsp; &nbsp; &nbsp;Hematocrit <strong>&gt;48%</strong> in women&nbsp;</p>\n<p>2. Bone marrow biopsy showing <strong>hypercellularity</strong> with <strong>trilineage hyperplasia</strong>&nbsp;(panmyelosis) and prominent erythroid, granulocytic, and megakaryocytic proliferation with pleomorphic mature megakaryocytes in the bone marrow, and&nbsp;</p>\n<p>3. Presence of&nbsp;<strong>JAK2 exon 12</strong> mutation</p>\n<p><span><strong>Minor criterion:</strong></span></p>\n<p>Subnormal serum erythropoietin level</p>\n<p>Diagnosis of polycythemia vera requires meeting either all 3 major criteria&nbsp;or the first 2 major criteria along with the minor criterion</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4304",
      "difficulty": "medium"
    },
    {
      "text": "A 45-year-old man is found to have a hemoglobin level of 18 g/dl, a hematocrit of 54%, and an elevated erythropoietin level. Which of the following is the least likely diagnosis?",
      "choices": [
        {
          "id": 1,
          "text": "Carbon monoxide poisoning"
        },
        {
          "id": 2,
          "text": "Cerebellar hemangioblastoma"
        },
        {
          "id": 3,
          "text": "Renal cell carcinoma"
        },
        {
          "id": 4,
          "text": "Polycythemia vera"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Polycythemia vera</strong> is associated with <strong>low or normal&nbsp;</strong>erythropoietin (<strong>EPO</strong>) levels.</p>\n<p>Polycythemia refers to an <strong>increase</strong> in the number of red blood cells (<strong>RBC</strong>) in the body. It is classified as:</p>\n<table>\n<tbody>\n<tr>\n<td>&nbsp;</td>\n<td><strong>Primary</strong> polycythemia (polycythemia vera)</td>\n<td><strong>Secondary </strong>polycythemia</td>\n</tr>\n<tr>\n<td>Pathophysiology</td>\n<td>Caused by mutations&nbsp;in the hematopoietic stem cells</td>\n<td>\n<p>Hypoxia (COPD,&nbsp;<strong>carbon monoxide</strong> poisoning)&nbsp;</p>\n<p>Autonomous EPO production&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td>Erythropoietin (EPO)</td>\n<td><strong>Normal or low</strong></td>\n<td>High</td>\n</tr>\n<tr>\n<td>WBCs, and platelet count&nbsp;</td>\n<td>High (due to increased production of all cell lines)</td>\n<td>Normal</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>Autonomous production of erythropoietin occurs in renal cell carcinoma (<strong>RCC</strong>), hepatocellular carcinoma, <strong>cerebellar</strong>&nbsp;<strong>hemangioblastoma</strong>.</p>\n<p><strong>Relative </strong>(spurious) polycythemia<strong>&nbsp;</strong>refers to an apparent increase in&nbsp;RBC or hemoglobin count due to a decrease in the plasma volume. It is commonly seen in&nbsp;<strong>dehydration</strong>.</p><hr><h3>Related Pearl: WHO Polycythemia Vera Criteria</h3><p><span><strong>Major criteria:</strong></span></p>\n<p>1. Hemoglobin <strong>&gt;16.5 g/dL</strong> in men</p>\n<p>&nbsp; &nbsp; &nbsp;Hemoglobin <strong>&gt;16.0 g/dL</strong> in women&nbsp;</p>\n<p>Or</p>\n<p>&nbsp; &nbsp; &nbsp;Hematocrit <strong>&gt;49%</strong> in men</p>\n<p>&nbsp; &nbsp; &nbsp;Hematocrit <strong>&gt;48%</strong> in women&nbsp;</p>\n<p>2. Bone marrow biopsy showing <strong>hypercellularity</strong> with <strong>trilineage hyperplasia</strong>&nbsp;(panmyelosis) and prominent erythroid, granulocytic, and megakaryocytic proliferation with pleomorphic mature megakaryocytes in the bone marrow, and&nbsp;</p>\n<p>3. Presence of&nbsp;<strong>JAK2 exon 12</strong> mutation</p>\n<p><span><strong>Minor criterion:</strong></span></p>\n<p>Subnormal serum erythropoietin level</p>\n<p>Diagnosis of polycythemia vera requires meeting either all 3 major criteria&nbsp;or the first 2 major criteria along with the minor criterion</p><hr><h3>Related Pearl: Comparison between Properties of Various Types of Polycythemia</h3><table>\n<tbody>\n<tr>\n<td>&nbsp;</td>\n<td>Plasma volume</td>\n<td>RBC Mass</td>\n<td>O<sub>2&nbsp;</sub>saturation</td>\n<td>EPO concentration</td>\n</tr>\n<tr>\n<td>\n<p>Relative</p>\n<p>polycythemia</p>\n</td>\n<td><strong>&nbsp; &nbsp; &darr;</strong></td>\n<td><strong>N</strong></td>\n<td><strong>N</strong></td>\n<td><strong>N</strong></td>\n</tr>\n<tr>\n<td>\n<p>Polycythemia</p>\n<p>vera</p>\n</td>\n<td><strong>&nbsp; &nbsp; &uarr;</strong></td>\n<td><strong> &uarr;</strong></td>\n<td><strong>N</strong></td>\n<td><strong>&nbsp; &darr;</strong></td>\n</tr>\n<tr>\n<td>\n<p>EPO- producing tumors</p>\n</td>\n<td><strong>N</strong></td>\n<td><strong> &uarr;</strong></td>\n<td><strong>N</strong></td>\n<td><strong> &uarr;</strong></td>\n</tr>\n<tr>\n<td>\n<p>Hypoxia</p>\n<p>(High altitude)</p>\n</td>\n<td><strong>N</strong></td>\n<td><strong> &uarr;</strong></td>\n<td><strong>&nbsp; &darr;</strong></td>\n<td><strong> &uarr;</strong></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>EPO: Erythropoietin</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4310",
      "difficulty": "medium"
    },
    {
      "text": "What is the most common cytogenetic abnormality in patients with polycythemia vera?",
      "choices": [
        {
          "id": 1,
          "text": "JAK6 mutation"
        },
        {
          "id": 2,
          "text": "JAK2 mutation"
        },
        {
          "id": 3,
          "text": "JAK8 mutation"
        },
        {
          "id": 4,
          "text": "JAK4 mutation"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The most common cytogenetic abnormality in <strong>polycythemia vera</strong> is the <strong>JAK2 mutation</strong>.&nbsp;</p>\n<p>JAK2 mutations can be found in the following neoplasms:</p>\n<ul>\n<li>Polycythemia vera</li>\n<li>Essential thrombocythemia</li>\n<li>Primary myelofibrosis</li>\n</ul>\n<p>&nbsp;</p><hr><h3>Related Pearl: WHO Polycythemia Vera Criteria</h3><p><span><strong>Major criteria:</strong></span></p>\n<p>1. Hemoglobin <strong>&gt;16.5 g/dL</strong> in men</p>\n<p>&nbsp; &nbsp; &nbsp;Hemoglobin <strong>&gt;16.0 g/dL</strong> in women&nbsp;</p>\n<p>Or</p>\n<p>&nbsp; &nbsp; &nbsp;Hematocrit <strong>&gt;49%</strong> in men</p>\n<p>&nbsp; &nbsp; &nbsp;Hematocrit <strong>&gt;48%</strong> in women&nbsp;</p>\n<p>2. Bone marrow biopsy showing <strong>hypercellularity</strong> with <strong>trilineage hyperplasia</strong>&nbsp;(panmyelosis) and prominent erythroid, granulocytic, and megakaryocytic proliferation with pleomorphic mature megakaryocytes in the bone marrow, and&nbsp;</p>\n<p>3. Presence of&nbsp;<strong>JAK2 exon 12</strong> mutation</p>\n<p><span><strong>Minor criterion:</strong></span></p>\n<p>Subnormal serum erythropoietin level</p>\n<p>Diagnosis of polycythemia vera requires meeting either all 3 major criteria&nbsp;or the first 2 major criteria along with the minor criterion</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4309",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following statements about polycythemia vera is true?",
      "choices": [
        {
          "id": 1,
          "text": "Risk of thrombosis strongly correlates with the degree of thrombocytosis"
        },
        {
          "id": 2,
          "text": "Generalized pruritus is a consequence of mast cell activation by JAK 2 mutation"
        },
        {
          "id": 3,
          "text": "It is protective against H.pylori infection"
        },
        {
          "id": 4,
          "text": "Acute myeloid leukemia is the most common cause of mortality"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Generalized pruritus</strong> seen in polycythemia vera (PV) is a consequence of the <strong>activation of mast cells by JAK 2 mutation</strong>.</p>\n<p>Other options:</p>\n<p>Option A: The risk of <strong>thrombosis</strong> strongly correlates with <strong>erythrocytosis</strong>, <strong>not</strong> the <strong>degree of thrombocytosis</strong>.</p>\n<p>Option C: In polycythemia vera, there is an <strong>increased risk of H.pylori infection</strong>.</p>\n<p>Option D: <strong>Thrombosis</strong> is the <strong>major cause of mortality</strong> in polycythemia vera. The incidence of acute leukemia in patients not exposed to chemotherapy or radiation therapy is low.</p>\n<p>PV is a <strong>clonal hematopoietic stem cell disorder</strong> in which red cells, granulocytes &amp; platelets accumulate in the absence of a physiological stimulus. The most common mutation seen in PV is the <strong>JAK2 mutation</strong>.</p><p>Clinical features of polycythemia vera are:</p>\n<ul>\n<li><strong>Thrombosis</strong> is the most common manifestation and is the major cause of mortality. Uncontrolled erythrocytosis causes increased viscosity of the blood causing thrombosis of the vessels. Patients may present with stroke, transient ischemic attacks, myocardial infarction, and Budd-Chiari syndrome.</li>\n<li><strong>Aquagenic pruritis</strong> is generalized itching following a warm bath or a shower due to increased mast cells and histamine.</li>\n<li><strong>Erythromelalgia</strong> is erythema and pain in the fingers, hands, and feet due to increased platelet stickiness.</li>\n<li><strong>Splenomegaly</strong> due to increased destruction of RBCs in the spleen</li>\n<li><strong>Gout</strong> is due to the excessive proliferation of the marrow cells leading to <strong>elevated uric acid levels</strong>.</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4291",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following would not be seen in patients with polycythemia vera?",
      "choices": [
        {
          "id": 1,
          "text": "Elevated platelet count"
        },
        {
          "id": 2,
          "text": "Elevated serum lactate dehydrogenase"
        },
        {
          "id": 3,
          "text": "Low to normal erythropoietin levels"
        },
        {
          "id": 4,
          "text": "Low WBC count"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>Low WBC count is not a feature of <strong>polycythemia vera</strong>. It is associated with an&nbsp;<strong>elevated WBC</strong> count.</p>\n<p>Common laboratory findings of polycythemia vera are:</p>\n<ul>\n<li>Elevated hemoglobin concentration, hematocrit levels, and RBC count</li>\n<li>Elevated WBCs and platelet counts</li>\n<li>Low to normal erythropoietin levels</li>\n<li class=\"p2\">Elevated serum lactate dehydrogenase</li>\n</ul><hr><h3>Related Pearl: WHO Polycythemia Vera Criteria</h3><p><span><strong>Major criteria:</strong></span></p>\n<p>1. Hemoglobin <strong>&gt;16.5 g/dL</strong> in men</p>\n<p>&nbsp; &nbsp; &nbsp;Hemoglobin <strong>&gt;16.0 g/dL</strong> in women&nbsp;</p>\n<p>Or</p>\n<p>&nbsp; &nbsp; &nbsp;Hematocrit <strong>&gt;49%</strong> in men</p>\n<p>&nbsp; &nbsp; &nbsp;Hematocrit <strong>&gt;48%</strong> in women&nbsp;</p>\n<p>2. Bone marrow biopsy showing <strong>hypercellularity</strong> with <strong>trilineage hyperplasia</strong>&nbsp;(panmyelosis) and prominent erythroid, granulocytic, and megakaryocytic proliferation with pleomorphic mature megakaryocytes in the bone marrow, and&nbsp;</p>\n<p>3. Presence of&nbsp;<strong>JAK2 exon 12</strong> mutation</p>\n<p><span><strong>Minor criterion:</strong></span></p>\n<p>Subnormal serum erythropoietin level</p>\n<p>Diagnosis of polycythemia vera requires meeting either all 3 major criteria&nbsp;or the first 2 major criteria along with the minor criterion</p><hr><h3>Related Pearl: Comparison between Properties of Various Types of Polycythemia</h3><table>\n<tbody>\n<tr>\n<td>&nbsp;</td>\n<td>Plasma volume</td>\n<td>RBC Mass</td>\n<td>O<sub>2&nbsp;</sub>saturation</td>\n<td>EPO concentration</td>\n</tr>\n<tr>\n<td>\n<p>Relative</p>\n<p>polycythemia</p>\n</td>\n<td><strong>&nbsp; &nbsp; &darr;</strong></td>\n<td><strong>N</strong></td>\n<td><strong>N</strong></td>\n<td><strong>N</strong></td>\n</tr>\n<tr>\n<td>\n<p>Polycythemia</p>\n<p>vera</p>\n</td>\n<td><strong>&nbsp; &nbsp; &uarr;</strong></td>\n<td><strong> &uarr;</strong></td>\n<td><strong>N</strong></td>\n<td><strong>&nbsp; &darr;</strong></td>\n</tr>\n<tr>\n<td>\n<p>EPO- producing tumors</p>\n</td>\n<td><strong>N</strong></td>\n<td><strong> &uarr;</strong></td>\n<td><strong>N</strong></td>\n<td><strong> &uarr;</strong></td>\n</tr>\n<tr>\n<td>\n<p>Hypoxia</p>\n<p>(High altitude)</p>\n</td>\n<td><strong>N</strong></td>\n<td><strong> &uarr;</strong></td>\n<td><strong>&nbsp; &darr;</strong></td>\n<td><strong> &uarr;</strong></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>EPO: Erythropoietin</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4303",
      "difficulty": "medium"
    },
    {
      "text": "A 40-year-old man presents with a 1-month history of severe itching every time he takes a hot shower. He also reports a burning sensation in his fingers and frequent headaches. His hemoglobin is 18 g/dL and his EPO levels are low. Which of the following can provide symptomatic relief in this patient?",
      "choices": [
        {
          "id": 1,
          "text": "Dabrafenib"
        },
        {
          "id": 2,
          "text": "Nilotinib"
        },
        {
          "id": 3,
          "text": "Eculizumab"
        },
        {
          "id": 4,
          "text": "Ruxolitinib"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>This clinical scenario is suggestive of <strong>polycythemia vera</strong>. In these patients,&nbsp;<strong>ruxolitinib,</strong>&nbsp;a&nbsp;Janus-kinase inhibitor is used to provide <strong>symptomatic relief</strong>.&nbsp;</p>\n<p>The treatment of polycythemia vera is as follows:</p>\n<ul class=\"ul1\">\n<li class=\"li1\">Therapeutic <strong>phlebotomy -&nbsp;</strong>definitive treatment</li>\n<li>Anticoagulants - in patients with thrombosis</li>\n<li class=\"li1\">Symptomatic relief:\n<ul>\n<li class=\"li1\">Ruxolitinib</li>\n<li class=\"li1\">Hydroxyurea</li>\n<li class=\"li1\">Interferon-alpha</li>\n<li class=\"li1\">PUVA therapy</li>\n</ul>\n</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4306",
      "difficulty": "medium"
    },
    {
      "text": "You are a first-year medicine resident. While examining a patient, you note that his spleen is enlarged 8.5 cm below his costal margin. You would include all of the following in your differential diagnosis except:",
      "choices": [
        {
          "id": 1,
          "text": "Essential thrombocythemia"
        },
        {
          "id": 2,
          "text": "Chronic myeloid leukemia"
        },
        {
          "id": 3,
          "text": "Primary myelofibrosis"
        },
        {
          "id": 4,
          "text": "Polycythemia vera"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>Enlargement of the spleen <strong>&gt; 8 cm</strong> below the costal margin or weight &gt; 1000 g is called <strong>massive splenomegaly</strong>. It is not a feature of<strong>&nbsp;essential thrombocythemia</strong> (ET), as it causes only <strong>mild splenomegaly</strong>.</p>\n<p>The causes of <strong>massive splenomegaly</strong> include:</p>\n<ul>\n<li>Chronic myeloid leukemia</li>\n<li>Primary myelofibrosis</li>\n<li>Polycythemia vera</li>\n<li>Chronic lymphocytic leukemia</li>\n<li>Lymphoma</li>\n<li>Hairy cell leukemia</li>\n<li>Gaucher's disease</li>\n<li>Sarcoidosis</li>\n<li>Autoimmune hemolytic anemia</li>\n</ul>\n<p>ET is a neoplasm in which the body produces too many platelets, resulting in&nbsp;a platelet count&nbsp;<strong>&gt; 4.5 lakhs/&mu;L.</strong>&nbsp;It occurs due to the mutations in the&nbsp;<strong>JAK2, CALR, </strong>or<strong>&nbsp;MPL</strong> genes.</p>\n<p>The majority of the patients are <strong>asymptomatic</strong> and are diagnosed incidentally.&nbsp;Some patients may present with <strong>thrombotic events</strong>&nbsp;or rarely, hemorrhages. The following findings are seen:</p>\n<ul>\n<li>Peripheral smear - abnormally<strong> large platelets</strong></li>\n<li>Bone marrow biopsy - increased number of <strong>megakaryocytes,&nbsp;</strong>with hyperlobulated nuclei</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4288",
      "difficulty": "hard"
    },
    {
      "text": "A 24-year-old woman, who was diagnosed with essential thrombocythemia, is being planned for cytoreductive therapy. What first-line drug should she be started on?",
      "choices": [
        {
          "id": 1,
          "text": "Anagrelide"
        },
        {
          "id": 2,
          "text": "Busulfan"
        },
        {
          "id": 3,
          "text": "Interferon alpha"
        },
        {
          "id": 4,
          "text": "Hydroxyurea"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The <strong>first-line drug</strong> for <strong>cytoreductive</strong> therapy in patients with<strong> essential thrombocythemia</strong> is <strong>hydroxyurea. </strong></p>\n<p>Treatment of essential thrombocythemia is as follows:</p>\n<ul>\n<li>No symptoms or risk of thrombosis:\n<ul>\n<li>Observation alone</li>\n<li>Low dose aspirin may be considered</li>\n</ul>\n</li>\n<li>High risk of thrombosis (cardiovascular risk factors, prior history of thrombosis)\n<ul>\n<li>Low dose aspirin</li>\n<li>Cytoreduction with hydroxyurea, busulfan, or interferon-alpha</li>\n</ul>\n</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4317",
      "difficulty": "medium"
    },
    {
      "text": "A 60-year-old man was referred with severe anemia and hepatosplenomegaly. Peripheral smear showed teardrop cells, nucleated RBCs, and giant abnormal platelets. Bone marrow aspirate could not be obtained despite multiple attempts, hence a bone marrow biopsy was done. The findings are given below. What is the most likely diagnosis?",
      "choices": [
        {
          "id": 1,
          "text": "Polycythemia vera"
        },
        {
          "id": 2,
          "text": "Essential thrombocythemia"
        },
        {
          "id": 3,
          "text": "Primary myelofibrosis"
        },
        {
          "id": 4,
          "text": "Chronic myeloid leukemia"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The image shows the deposition of numerous collagen fibers in the bone marrow, which indicates <strong>marrow fibrosis</strong>. These clinical findings and history of a <strong>dry tap</strong> on bone marrow aspiration are diagnostic of <strong>primary myelofibrosis</strong>.</p>\n<p>In this condition, the neoplastic proliferation of hematopoietic stem cells results in increased and <strong>abnormal proliferation</strong> of the <strong>megakaryocytes</strong>. These megakaryocytes release excessive amounts of platelet-derived growth factor (<strong>PDGF</strong>) and<strong> TGF-&beta;</strong>. Increased growth factors lead to the deposition of collagen in the bone marrow which eventually leads to fibrosis.&nbsp;</p>\n<p>The clinical features include:</p>\n<ul>\n<li>Early phase:\n<ul>\n<li>Thrombocytosis (large, abnormal platelets) and leukocytosis</li>\n<li><strong>Hypercellularity </strong>of bone marrow</li>\n</ul>\n</li>\n<li>Late phase:\n<ul>\n<li>Pancytopenia&nbsp;</li>\n<li><strong>Hypocellularity</strong>&nbsp;and <strong>fibrosis</strong> of bone marrow (<strong>dry tap</strong>)</li>\n<li>Teardrop-shaped RBCs and leukoerythroblastosis (premature release of nucleated erythroid and early granulocytes into blood)</li>\n</ul>\n</li>\n<li><strong>Hepatosplenomegaly&nbsp;</strong>- due to extramedullary hematopoiesis.</li>\n</ul><p>The FDA approved <strong>fedratinib,&nbsp;</strong>a <strong>JAK2-selective inhibitor&nbsp;</strong>for the treatment of adult patients with intermediate or high-risk primary or secondary myelofibrosis.</p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/edbcad7a529649c5a22b29a233ab1c75.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4314",
      "difficulty": "medium"
    },
    {
      "text": "Bone marrow aspirate of a patient with pancytopenia revealed a hypercellular marrow. Which of the following conditions is unlikely?",
      "choices": [
        {
          "id": 1,
          "text": "Paroxysmal nocturnal hemoglobinuria"
        },
        {
          "id": 2,
          "text": "Fanconi anemia"
        },
        {
          "id": 3,
          "text": "Megaloblastic anemia"
        },
        {
          "id": 4,
          "text": "Myelodysplastic syndrome"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Fanconi anemia</strong>&nbsp;results in pancytopenia with <strong>hypocellular</strong> <strong>bone marrow</strong>. Hence, it is not likely in this patient.</p>\n<p>Causes of <strong>pancytopenia</strong> with <strong>hypocellular</strong> bone marrow include:</p>\n<ul>\n<li>Inherited <strong>aplastic anemia</strong>\n<ul>\n<li>Fanconi anemia</li>\n<li>Dyskeratosis congenita</li>\n<li>Shwachman-Diamond syndrome</li>\n</ul>\n</li>\n<li>Acquired aplastic anemia</li>\n</ul>\n<p>Causes of <strong>pancytopenia</strong> with <strong>hypercellular</strong> bone marrow include:</p>\n<ul>\n<li>Primary bone marrow disorders\n<ul>\n<li>Paroxysmal nocturnal hemoglobinuria<strong> (PNH)</strong></li>\n<li><strong>Myelodysplastic </strong>syndrome</li>\n<li>Myelofibrosis</li>\n</ul>\n</li>\n<li>Systemic diseases\n<ul>\n<li><strong>Megaloblastic anemia</strong></li>\n<li>Alcoholism</li>\n<li>Sarcoidosis</li>\n<li>Tuberculosis</li>\n<li>Brucellosis</li>\n</ul>\n</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4319",
      "difficulty": "medium"
    },
    {
      "text": "A 20-year-old male patient with the following exam findings is found to have pancytopenia. What is the most likely diagnosis?",
      "choices": [
        {
          "id": 1,
          "text": "Fanconi anemia"
        },
        {
          "id": 2,
          "text": "Shwachman-Diamond syndrome"
        },
        {
          "id": 3,
          "text": "Diamond-Blackfan syndrome"
        },
        {
          "id": 4,
          "text": "Dyskeratosis congenita"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The most likely diagnosis is <strong>dyskeratosis congenita. </strong>This condition is characterized by <strong>pancytopenia&nbsp;</strong>along with<strong>&nbsp;</strong>the clinical triad of:</p>\n<ol>\n<li>Reticular skin pigmentation&nbsp;</li>\n<li>Nail&nbsp;dystrophy</li>\n<li>Oral leukoplakia&nbsp;</li>\n</ol>\n<p>&nbsp;</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/170d5aeff3914cea903edffc82a81e60x1280x2771.JPEG\" alt=\"Explanation Image\"><p>Option A: Fanconi anemia&nbsp;is an autosomal recessive disorder characterized by pancytopenia, congenital anomalies, and an increased risk of malignancies.</p>\n<p>Option B:&nbsp;Shwachman-Diamond syndrome presents with bone marrow failure and exocrine pancreatic insufficiency.</p>\n<p>Option C: Diamond-Blackfan syndrome presents with low RBC counts due to congenital erythroid aplasia.</p>\n<p>Note: Fanconi anemia is different from Fanconi syndrome.&nbsp;Fanconi syndrome&nbsp;is a disorder of renal tubular function (type 2 RTA)&nbsp;that results in increased excretion of glucose, amino acids, bicarbonates, and phosphates.</p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/68b4a3195abe4b2f8fb640974cee72a7.PNG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4322",
      "difficulty": "medium"
    },
    {
      "text": "All of the following can cause acquired aplastic anemia except:",
      "choices": [
        {
          "id": 1,
          "text": "Cyclophosphamide therapy"
        },
        {
          "id": 2,
          "text": "Radiation exposure"
        },
        {
          "id": 3,
          "text": "Paroxysmal nocturnal hemoglobinuria"
        },
        {
          "id": 4,
          "text": "Herpes simplex infection"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>Herpes simplex infection is not a cause of&nbsp;<strong>acquired aplastic anemia</strong>.</p>\n<p>Secondary causes of acquired aplastic anemia include:</p>\n<ul>\n<li><strong>Radiation</strong></li>\n<li>Toxins - Benzene</li>\n<li>Drugs&nbsp;\n<ul>\n<li>Chemotherapy drugs (including <strong>cyclophosphamide</strong>)</li>\n<li>Sulfonamides</li>\n<li>Chloramphenicol</li>\n</ul>\n</li>\n<li>Infections:&nbsp;\n<ul>\n<li>1-2 months after an attack of seronegative&nbsp;viral hepatitis</li>\n<li>HIV, EBV, CMV</li>\n<li>Parvovirus B19</li>\n</ul>\n</li>\n<li>Eosinophilic fasciitis</li>\n<li><strong>Paroxysmal nocturnal hemoglobinuria&nbsp;</strong></li>\n<li>Graft vs host disease</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1204",
      "difficulty": "medium"
    },
    {
      "text": "A 25-year-old lady is being evaluated for recurrent epistaxis. On examination, the spleen is not palpable. Investigations reveal Hb of 6 g/dL, platelet count of 18,000/μL, and WBC count of 3000/μL. The results of a bone marrow biopsy are given below. What is the best method of management in this patient?",
      "choices": [
        {
          "id": 1,
          "text": "Administer hematopoietic growth factors"
        },
        {
          "id": 2,
          "text": "Umbilical cord blood transplantation"
        },
        {
          "id": 3,
          "text": "Hematopoietic stem cell transplantation"
        },
        {
          "id": 4,
          "text": "Antithymocyte globulin with cyclosporine"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The clinical and laboratory findings, as well as bone marrow hypocellularity are diagnostic of <strong>aplastic anemia</strong>. In this young patient, the best method of management is&nbsp;<strong>hematopoietic stem cell transplantation.</strong></p>\n<p>Aplastic anemia presents with pancytopenia and resulting bleeding manifestations, anemia, and frequent infections.&nbsp;Bone marrow biopsy reveals&nbsp;<strong>hypocellularity</strong> with&nbsp;<strong>fatty infiltration</strong>&nbsp;of the bone marrow. The management is as follows:</p>\n<ul>\n<li>Hematopoietic <strong>stem cell transplantation</strong>&nbsp;- best method of management in <strong>young patients</strong></li>\n<li><strong>Antithymocyte globulin</strong>&nbsp;with <strong>cyclosporine - </strong>elderly patients and patients without HLA-matched donors</li>\n<li><strong>Eltrombopag</strong> - a thrombopoietin analog used as add-on therapy</li>\n</ul>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/a0ad396188a846ff98c7b376a62c296a.PNG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1206",
      "difficulty": "easy"
    },
    {
      "text": "What is the most common cytogenetic abnormality seen in patients with myelodysplastic neoplasm?",
      "choices": [
        {
          "id": 1,
          "text": "7q deletion"
        },
        {
          "id": 2,
          "text": "5q deletion"
        },
        {
          "id": 3,
          "text": "Monosomy 5"
        },
        {
          "id": 4,
          "text": "Monosomy 7"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The most common cytogenetic abnormality seen in <strong>myelodysplastic</strong>&nbsp;<strong>neoplasm</strong>&nbsp;is the <strong>5q deletion.&nbsp;</strong></p>\n<p>Myelodysplastic syndromes/neoplasm (MDS) are a group of disorders in which <strong>abnormal stem cells</strong> produce increased numbers of <strong>immature blood cells</strong>. These immature cells are defective and die prematurely resulting in lower numbers of mature blood cells. It is characterized by&nbsp;<strong>pancytopenia&nbsp;</strong>and a high risk of acute myeloid leukemia (<strong>AML</strong>).</p>\n<p>The cytogenetic abnormalities identified in this condition include:</p>\n<ul>\n<li>5q deletion</li>\n<li>3q deletion</li>\n<li>7q deletion</li>\n<li>Monosomy 7</li>\n<li>Monosomy 5</li>\n</ul>\n<p><strong>5th edition WHO Classification of MDS (2022):</strong></p>\n<p><strong>1. MDS with defining genetic abnormalities:</strong></p>\n<ul>\n<li aria-level=\"1\">MDS with a low blast and isolated 5q deletion (MDS-5q): &lt;5% blasts in the bone marrow or &lt;2% blasts in the peripheral blood.&nbsp;</li>\n<li aria-level=\"1\">MDS with a low blast and SF3B1 mutation (MDS-SF3B1): Detection of &ge;15% ring sideroblasts may substitute for SF3B1 mutation.&nbsp;&nbsp;</li>\n<li aria-level=\"1\">MDS with biallelic TP53 inactivation (MDS-biTP53): &lt;20% blasts in the bone marrow or peripheral blood.</li>\n</ul>\n<p><strong>2. MDS, morphologically defined:</strong></p>\n<ul>\n<li aria-level=\"1\">MDS with low blasts: &lt;5% blasts in the bone marrow or &lt;2% blasts in the peripheral blood.&nbsp;</li>\n<li aria-level=\"1\">MDS-hypoplastic: &le;25% bone marrow cellularity</li>\n<li aria-level=\"1\">MDS with increased blasts (IB):\n<ul>\n<li aria-level=\"1\">MDS-IB1: 5&ndash;9% of blasts in bone marrow or 2&ndash;4% in peripheral blood</li>\n<li aria-level=\"1\">MDS-IB2:10-19% of blasts in bone marrow or 5-19% in peripheral blood or Auer rods</li>\n</ul>\n</li>\n<li aria-level=\"1\">MDS-fibrosis: 5-19% of blasts in bone marrow or 2&ndash;19% in peripheral blood</li>\n</ul>\n<p><strong>3. Childhood myelodysplastic neoplasm:</strong></p>\n<ul>\n<li aria-level=\"1\">Childhood MDS with low blasts:&lt;5% blasts in the bone marrow or &lt;2% blasts in the peripheral blood</li>\n<li aria-level=\"1\">Childhood MDS with increased blasts: 5-19% blasts in the bone marrow or 2-19% blasts in the peripheral blood.</li>\n</ul><hr><h3>Related Pearl: Bone Marrow Changes in Myelodysplastic Syndrome (MDS)</h3><p>The myelodysplastic syndrome can lead to dysplasia of the erythroid series, myeloid series, and megakaryocytes.</p>\n<p>Dysplasia of erythroid series:</p>\n<ul>\n<li><strong>Megaloblastoid maturation&nbsp;</strong>- Abnormally large erythroid cells</li>\n<li><strong>Nuclear budding abnormalities&nbsp;</strong>- Nucleus with abnormal shape</li>\n<li><strong>Ring sideroblasts&nbsp;</strong>- Erythroblasts with stainable iron in the cytoplasm&nbsp;</li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/5a79f916cf5b46d2a1ad0f781dddef8dx798x599.JPEG\" alt=\"Pearl Image\"><p>&nbsp;</p>\n<p>Dysplasia of myeloid series:</p>\n<ul>\n<li>Neutrophils with a decreased number of secondary granules</li>\n<li class=\"p1\"><strong>Pseudo-Pelger-Hüet cells</strong>- neutrophils with only <strong>two nuclear lobes</strong></li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/8fff2b32c6624e1da540ca3d292db163x359x512.JPEG\" alt=\"Pearl Image\"><p class=\"p1\">&nbsp;</p>\n<p class=\"p1\">Dysplasia of the megakaryocytes:</p>\n<ul>\n<li class=\"p1\">Megakaryocyte with single nuclear lobe</li>\n<li class=\"p1\"><strong>Pawn ball megakaryocytes</strong>- cells with multiple separate nuclei</li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/bc059ad7c9c0487cad202d46105ccdafx512x465.PNG\" alt=\"Pearl Image\"><p>If only one lineage is affected, then it is called single lineage dysplasia. If multiple lineages are affected, then it is called multilineage dysplasia. If the percentage of ring sideroblasts is more than 15% it is called MDS with ring sideroblasts (MDS-RS).</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1209",
      "difficulty": "medium"
    },
    {
      "text": "A patient with myelodysplastic syndrome was found to have 5q deletion. What is the drug of choice for this patient?",
      "choices": [
        {
          "id": 1,
          "text": "Cyclosporine"
        },
        {
          "id": 2,
          "text": "Cyclophosphamide"
        },
        {
          "id": 3,
          "text": "Thalidomide"
        },
        {
          "id": 4,
          "text": "Lenalidomide"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Lenalidomide</strong> is the drug of choice in patients with myelodysplastic syndrome (<strong>MDS</strong>) associated with <strong>5q deletion</strong>.</p>\n<p>It is a thalidomide derivative with the following benefits in these patients:</p>\n<ul>\n<li>Patients achieve transfusion independence</li>\n<li>Normal or near-normal hemoglobin levels</li>\n<li>Normalization of cytogenetics&nbsp;</li>\n</ul>\n<p>Adverse effects include:</p>\n<ul>\n<li>Myelosuppression (worsening thrombocytopenia and neutropenia, necessitating blood count monitoring)&nbsp;</li>\n<li>Deep vein thrombosis and pulmonary embolism</li>\n</ul>\n<p>However, <strong>hematopoietic stem cell transplant&nbsp;</strong>remains the&nbsp;definitive treatment.</p><p>The FDA recently approved a combination of decitabine, a nucleoside metabolic inhibitor, and cedazuridine, a cytidine deaminase inhibitor, for the treatment of adult patients with myelodysplastic syndromes (MDS)&nbsp;and chronic myelomonocytic leukemia (CMML).&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1210",
      "difficulty": "medium"
    }
  ]
}